Global News Wire: Novavax Initiating Human Clinical Trials for H7N9 Virus
Novavax, Inc (NVAX) is a clinical-stage biopharmaceutical company that strives to create novel vaccines to treat a broad spectrum of diseases around the world.
Month: July 2013
Pharma Live: Cytokinetics amending errors in Amyotrophic Lateral Sclerosis Phase IIB Study
Cytokinetics (CYTK) is a clinical stage biotechnology company that focuses on the discovery and development of novel molecular therapeutics in relation to muscle function.
Cognoptix: Simple Eye-Scan Test a Powerful Tool for Diagnosing Alzheimer’s Disease
Cognoptix and its technology have the ability to overhaul commonly accepted Alzheimer’s Disease diagnostic practices, providing a tool to diagnose the disease at an early stage, thereby increasing the efficacy of current therapies.
BioCentury: Orexo is Dissolving Away Opioid Addiction with New Medication
Orexo is an emerging specialty pharmaceutical company in route to enter the market with their new medication Zubsolv; an oral medication that dissolves under the tongue to treat opioid addiction.
“The Value Proposition of the JOBS Act and Reg A” How Will Capital Market Structures Assess Valuation for Smaller Medical Technology Companies After the JOBS Act?
There has been much debate of how the capital market landscape is looking to shape up for bioscience companies with the impending implementation of the […]
Complexa: Novel Treatment for Contrast-Induced Acute Kidney Injury
The Contrast Induced Kidney market is a large one, at about $500 million. This is due to the fact that Acute Kidney Injury affects 3-7% of all patients admitted into hospitals and about 25-30% of patients admitted into the Intensive Care Unit. Complexa’s technology has the potential to treat an issue many sick Americans face today.